• TRIAL DATA

    Antibiotic plus immunotherapy combination shows activity in F. nucleatum-positive MSS metastatic CRC

    A multicenter phase 2 trial of 33 patients with Fusobacterium nucleatum-positive, microsatellite-stable metastatic CRC treated with tislelizumab, fruquintinib, and metronidazole achieved a median progression-free survival of 6.0 months, with an objective response rate of 19.4% and disease control rate of 83.9%. (Cancer Cell)